Drug Discovery & Development | Seattle Gentics-AbbVie Deal Expanded Zacks.com AbbVie will pay an upfront fee of $25 million for additional rights of using Seattle Genetics' ADC technology with AbbVie antibodies against oncology targets. Seattle Genetics could receive up to $255 million from AbbVie in the form of potential ... Seattle Genetics Further Expands Antibody-Drug Conjugate Collaboration with ... Seattle Genetics and AbbVie Broaden Cancer Partnership Seattle Genetics and AbbVie Broaden Partnership |
